Acquisition and Long-term Observation of Patients With Severe Allergic Reactions

计划入组 20,000 人 · 首次发布于 2022 年 1 月 27 日

Natural History of Severe Allergic Inflammation and Reactions

计划入组 945 人 · 首次发布于 2010 年 7 月 16 日

Predicting Peanut Anaphylaxis and Reducing Epinephrine

计划入组 51 人 · 首次发布于 2023 年 1 月 25 日

Hydrocortisone succinate(Solu-cortef)

C₂₅H₃₄O₈

Methylprednisolone hemisuccinate(Solu-medrol)

C₂₆H₃₄O₈

FFAR4 activator program (severe asthma)

Gossamer Bio

United States

Xencor

United States

NATIONAL INSTITUTE OF DISEASES OF THE CHEST AND HOSPITAL

Bangladesh

China Approves Neffy as First Community-Use Epinephrine Product for Severe Allergic Reactions

Neffy Nasal Spray Approved by FDA as Novel Anaphylaxis Treatment

mRNA-Lipid Nanoparticle Vaccine Shows Promise Against Severe Allergic Reactions in Preclinical Study